Business Wire

NC-LENOVO

8.9.2021 06:02:11 CEST | Business Wire | Press release

Share
Lenovo Launches Global Everything-as-a-Service Strategy

Today, at its annual Tech World event, Lenovo announced an evolution in its consumption-based business model, introducing Lenovo TruScale , a new portfolio-spanning everything-as-a-service offering. This announcement is part of Lenovo’s continuing transformation for the next reality – a new era where consumers and business leaders need new solutions and technologies to face unprecedented change in business, education, living and beyond.

Expanding its TruScale brand beyond infrastructure services, Lenovo is bringing all of its as-a-service offerings under one umbrella to provide a truly global solution that makes everything from the pocket to the cloud available via a single contract framework. Lenovo TruScale embodies the company’s vision and transformation for the next reality – meeting the growing global demand for smarter technology amid a new era of hybrid working and learning.

“Digital transformation is accelerating faster than ever, and companies are struggling to keep pace with the speed of innovation. We hear from CIOs every day that their organizations’ technology needs are evolving every 12-18 months,” said Ken Wong, president of Solutions & Services Group. “With Lenovo TruScale, customers can expect one solution, one provider, one contract framework, and a single point of accountability for everything-as-a-service.”

Lenovo TruScale offers businesses of all sizes an everything-as-a-service platform with the flexibility they need to stay competitive with a scalable, cloud-like consumption model and predictable payment options for hardware and service inclusions. This transition to a fully integrated as-a-service strategy brings to life the company’s “One Lenovo” vision – addressing common business challenges and providing IT leaders with the performance and flexibility to pay-as-you-grow. With Lenovo TruScale, IT leaders’ infrastructure solutions are fully managed, giving customers the advantages of an on-premise cloud environment along with the peace of mind around data management in a hybrid environment.

Research shows the as-a-service market is growing at four times the overall IT services total addressable market. In three years, as-a-service models will represent 12% of enterprise x86 server spend and over 50% of new enterprise storage spend, growing at 40% CAGR and around 17% of commercial PC spend, up from 1% two years ago and growing at 50% CAGR.1

As the world shifts to a flexible “work, learn and connect-from-anywhere” model, organizations that embrace smarter technology designed for a hybrid reality will benefit from this transition. This requires flexibility in devices and work platforms, on-demand support when and where needed, and customizable solutions across the organization, benefits that many will recognize from Lenovo’s existing Device-as-a-Service solution. Now moving under the new TruScale umbrella, Lenovo DaaS will continue to help customers move to a Modern IT environment by combining the best end-to-end technology from across Lenovo with lifecycle services and support and convenient financing to deliver lower total cost of ownership.

Lenovo is building a new way to deliver as-a-service to the market and offer organizations ultimate flexibility in how they leverage their IT infrastructure, services and software. By forming strategic alliances with other market leaders, customers can get the public cloud experience with the security and control of an on-premises solution. As part of this new platform, Lenovo has joined with leading infrastructure partners Deloitte, VMWare and Intel, and DaaS security partners Absolute Software and SentinelOne to provide organizations with various dynamic offerings such as hybrid cloud solutions for Edge to Cloud environments, best-in-class managed security solutions and access to the most current storage infrastructure innovation, for the life of their data, with the ability to scale storage capacity on demand.

“Lenovo’s as-a-service approach helps meet the market's demand for responsive, reliable hybrid cloud operations. Put simply our organizations are helping companies grow their enterprises and mitigate risks to create more value and serve society better,” said Punit Renjen, CEO of Deloitte Global.

Learn more about TruScale’s latest offerings at Lenovo’s annual global innovation event, Tech World .

1 Gartner, IDC, Lenovo Market Intelligence

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye